| James E. Sapirstein |
Founder of Tobira Therapeutics, Inc., James E. Sapirstein is a businessperson who has been at the helm of 6 different companies and currently is Chairman, President & Chief Executive Officer of AzurRx BioPharma, Inc. Mr. Sapirstein is also Director & Member-Emerging Companies at Biotechnology Innovation Organization and on the board of 5 other companies.
Mr. Sapirstein previously occupied the position of Chairman & Chief Executive Officer for Marizyme, Inc., Chief Executive Officer & Director at Hepion Pharmaceuticals, Inc., Manager-International Operations at Eli Lilly & Co., Director-International Marketing at Bristol Myers Squibb Co., Global Marketing Lead at Gilead Sciences, Inc., President, Chief Executive Officer & Director at Tobira Therapeutics, Inc., Chief Executive Officer & Director at Alliqua BioMedical, Inc., Product Director at Hoffmann-La Roche, Inc. and Executive Vice President-Metabolic & Endocrinology at EMD Serono, Inc.
He received an MBA from Fairleigh Dickinson University and an undergraduate degree from Rutgers State University of New Jersey. |
| Daniel H. Schneiderman |
Presently, Daniel H. Schneiderman occupies the position of Chief Financial Officer at AzurRx BioPharma, Inc.
In the past he held the position of Chief Financial Officer of Biophytis SA, Secretary, Vice President-Finance & Controller at MetaStat, Inc. and Vice President-Investment Banking at Burnham Hill Partners LLC.
Daniel H. Schneiderman received an undergraduate degree from Tulane University (Louisiana). |
| James E. Pennington |
Presently, James E. Pennington is Chief Medical Officer for AzurRx BioPharma, Inc. Dr. Pennington is also Clinical Professor at The University of California, San Francisco.
He previously held the position of Senior Vice President-Clinical Research at Shaman Pharmaceuticals, Inc., Chief Medical Officer & Executive Vice President at Anthera Pharmaceuticals, Inc., Secretary & General Counsel of Sun River Energy, Inc., Vice President-Biological Clinical Research at Bayer Corp., Senior Vice President-Medical & Scientific Affairs at InterMune, Inc., Chief Medical Officer & Executive Vice President at CoTherix, Inc., Senior VP-Research Development & Clinical Affairs at Alpha Therapeutic Corp., Interim Chief Medical Officer at Trius Therapeutics, Inc. and Professor at Harvard Medical School.
He received an undergraduate degree from the University of Oregon and a doctorate from Oregon Health & Science University. |
| Edward J. Borkowski |
Edward J. Borkowski is Executive Vice President-Operations for TherapeuticsMD, Inc. Mr. Borkowski is also on the board of Allegheny College, Acacia Pharma Ltd., AzurRx BioPharma, Inc. (former Chairman) and Acacia Pharma Group Plc and Member of The American Institute of Certified Public Accountants, Vice President at Mylan Institutional, Inc. and Member of New York State Society of Certified Public Accountants.
In his past career Mr. Borkowski held the position of Chief Financial Officer of Aceto Corp., Chief Financial Officer at MiMedx Group, Inc., Chief Financial Officer of Amerigen Pharmaceuticals Ltd., Director at Advanz Pharma Corp. Ltd., Chief Financial Officer of ConvaTec Group Plc Chief Financial Officer for ConvaTec, Inc. and Chief Financial Officer at Convatec Healthcare B SARL (both are subsidiaries of ConvaTec Group Plc), Engagement Manager at Merck & Co., Inc., Chief Financial Officer at Mylan Laboratories, Inc., Chief Financial Officer of Mylan, Inc., Chief Financial Officer at CareFusion Corp., Chief Financial Officer & Executive Vice President of Mylan NV, VP-Global Finance & Information Technology at Pharmacia Corp., Principal at Arthur Andersen LLP and Comptroller at Wyeth Corp.
Mr. Borkowski received an undergraduate degree from Allegheny College and an MBA from Rutgers State University of New Jersey. |
| Gregory Oakes |
Gregory Oakes is on the board of BioNJ, Inc. and AzurRx BioPharma, Inc. and Executive Vice President & President-North America at Vifor Pharma AG.
In the past Mr. Oakes was Vice President & Manager-US General at Celgene Corp., VP, Head-Managed Markets & Market Access at Novartis Pharmaceuticals Corp. and General Manager of Schering-Plough sro.
He received an undergraduate degree from Edinboro University of Pennsylvania and an MBA from Clemson University. |
| Charles J. Casamento |
Founder of Questcor Pharmaceuticals, Inc. and Indevus Pharmaceuticals, Inc., Charles J. Casamento is a businessperson who has been at the helm of 7 different companies and currently holds the position of Chairman for Relmada Therapeutics, Inc. Mr. Casamento is also Member-Science Council at Fordham University and Executive Director & Principal at The Sage Group and on the board of 5 other companies.
In his past career he held the position of Chairman of RespireRx Pharmaceuticals, Inc., President & Chief Executive Officer for Osteologix Holdings Plc and President & Chief Executive Officer at Osteologix, Inc. (a subsidiary of Osteologix Holdings Plc), VP-Business Development & Strategic Planning at Johnson & Johnson, Chairman, President & Chief Executive Officer at RiboGene, Inc., Chairman, President & Chief Executive Officer for Questcor Pharmaceuticals, Inc., President & Chief Executive Officer for Indevus Pharmaceuticals, Inc., Senior VP, GM-Pharmaceuticals & Biochemicals at Genzyme Corp., VP-Business Development & Strategic Planning at Sandoz, Inc., VP-Business Development & Strategic Planning at Hoffmann-La Roche, Inc. and VP-Business Development & Strategic Planning at American Hospital Supply Corp.
Mr. Casamento received an undergraduate degree from Fordham University and an MBA from Iona College. |
| Alastair J. Riddell |
Alastair J. Riddell is a businessperson who has been at the head of 14 different companies. Presently, he is Chairman for Nemesis Biosciences Ltd., Non-Executive Chairman at Nuformix Plc and Chairman for South West Peninsula AHSN Ltd. He is also on the board of Cristal Delivery BV and AzurRx BioPharma, Inc.
He previously occupied the position of Executive Chairman of Silence Therapeutics Plc, Non-Executive Chairman at Feedback Plc, Chairman of PCT Shareholders Ltd., Chairman of DefiniGEN Ltd., Chairman at Procure Therapeutics Ltd., Chief Executive Officer at Asset Realisation Co. Ltd. and Chief Executive Officer of Stem Cell Sciences Plc (a subsidiary of Asset Realisation Co. Ltd.), Chairman of Surface Therapeutics Ltd., Chief Executive Officer at Pharmagene Plc, Chief Executive Officer & Executive Director at Paradigm Therapeutics Ltd. and Chief Executive Officer at Bioseek UK Ltd.
He received an undergraduate degree and a doctorate from the University of Aston and a graduate degree from the University of Birmingham School. |
| Vern Lee Schramm |
Vern Lee Schramm is on the board of AzurRx BioPharma, Inc. and Professor at Albert Einstein College of Medicine, Inc.
Dr. Schramm received an undergraduate degree from Dakota State University, a graduate degree from Harvard University and a doctorate from Australian National University. |
